Metalloproteinase inhibition has differential effects on alloimmunity, autoimmunity, and histopathology in the transplanted lung

Transplantation

Volumn 83, Issue 6, 2007, Pages 799-808

  Yoshida, Shigetoshi ^a   Iwata, Takekazu ^a   Chiyo, Masako ^a   Smith, Gerald N ^a   Foresman, Brian H ^a   Mickler, Elizabeth A ^a   Heidler, Kathleen M ^a   Cummings, Oscar W ^a   Fujisawa, Takehiko ^b   Brand, David D ^c   Baker, Andrew ^d   Wilkes, David S ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHIBA UNIVERSITY   (Japan)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Autoimmunity; Cytokines; Posttransplant lymphoproliferative disorder; Rodent; Type V collagen

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ANTIGEN; AUTOANTIGEN; COLLAGEN TYPE 5; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG EFFECT; ENZYME INHIBITION; GENE THERAPY; HISTOPATHOLOGY; IMMUNOPATHOGENESIS; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AUTOIMMUNITY; COLLAGEN TYPE V; GRAFT REJECTION; HYPERSENSITIVITY, DELAYED; INTERLEUKIN-1BETA; LUNG TRANSPLANTATION; MALE; MATRIX METALLOPROTEINASES; RATS; RATS, INBRED F344; RATS, WISTAR; TETRACYCLINES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34147148652     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000258600.05531.5d     Document Type: Article

References (51)

1. Whelan TP, Hertz MI. Allograft rejection after lung transplantation. Clin Chest Med 2005; 26: 599.
2. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004; 4: 617.
3. Yano M, Omoto Y, Yamakawa Y, et al. Increased matrix metalloproteinase 9 activity and mRNA expression in lung ischemia-reperfusion injury. J Heart Lung Transplant 2001; 20: 679.
4. Soccal PM, Gasche Y, Miniati DN, et al. Matrix metalloproteinase inhibition decreases ischemia-reperfusion injury after lung transplantation. Am J Transplant 2004; 4: 41.
5. Hubner RH, Meffert S, Mundt U, et al. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. Eur Respir J 2005; 25: 494.
6. Taghavi S, Krenn K, Jaksch P, et al. Broncho-alveolar lavage matrix metalloproteases as a sensitive measure of bronchiolitis obliterans. Am J Transplant 2005; 5: 1548.
7. Fernandez FG, Campbell LG, Liu W, et al. Inhibition of obliterative airway disease development in murine tracheal allografts by matrix metalloproteinase-9 deficiency. Am J Transplant 2005; 5: 671.
8. Kawamata H, Kawai K, Kameyama S, et al. Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 1995; 63: 680.
9. Swiderski RE, Dencoff JE, Floerchinger CS, et al. Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am J Pathol 1998; 152: 821.
10. Kumagai K, Ohno I, Okada S, et al. Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol 1999; 162: 4212.
11. Mares DC, Heidler KM, Smith GN, et al. Type V collagen modulates alloantigen-induced pathology and immunology in the lung. Am J Respir Cell Mol Biol 2000; 23: 62.
12. Mizobuchi T, Yasufuku K, Zheng Y, et al. Differential expression of Smad7 transcripts identifies the CD4+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003; 171: 1140.
13. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol 2004; 286: L1129.
14. Yasufuku K, Heidler KM, O'Donnell PW, et al. Oral tolerance induction by type V collagen downregulates lung allograft rejection. Am J Respir Cell Mol Biol 2001; 25: 26.
15. Yasufuku K, Heidler KM, Woods KA, et al. Prevention of bronchiolitis obliterans in rat lung allografts by type V collagen-induced oral tolerance. Transplantation 2002; 73: 500.
16. Yoshida S, Haque A, Mizobuchi T, et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am J Transplant 2006; 6: 724.
17. Bharat A, Fields RC, Steward N, et al. CD4+25+ regulatory T cells limit Th1-autoimmunity by inducing IL-10 producing T cells following human lung transplantation. Am J Transplant 2006; 6: 1799.
18. Carney DE, Lutz CJ, Picone AL, et al. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass. Circulation 1999; 100: 400.
19. Carney DE, McCann UG, Schiller HJ, et al. Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res 2001; 99: 245.
20. Steinberg J, Halter J, Schiller HJ, et al. Metalloproteinase inhibition reduces lung injury and improves survival after cecal ligation and puncture in rats. J Surg Res 2003; 111: 185.
21. Vieillard-Baron A, Frisdal E, Eddahibi S, et al. Inhibition of matrix metalloproteinases by lung TIMP-1 gene transfer or doxycycline aggravates pulmonary hypertension in rats. Circ Res 2000; 87: 418.
22. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101: 1478.
23. George SJ, Johnson JL, Angelini GD, et al. Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointimal formation in human saphenous vein. Hum Gene Ther 1998; 9: 867.
24. Swanson KA, Zheng Y, Heidler KM, et al. CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase. Am J Respir Cell Mol Biol 2004; 30: 311.
25. Haque MA, Mizobuchi T, Yasufuku K, et al. Evidence for immune responses to a self-antigen in lung transplantation: role of type V collagen-specific T cells in the pathogenesis of lung allograft rejection. J Immunol 2002; 169: 1542.
26. Sekine Y, Yasufuku K, Heidler KM, et al. Monocyte chemoattractant protein-1 and RANTES are chemotactic for graft infiltrating lymphocytes during acute lung allograft rejection. Am J Respir Cell Mol Biol 2000; 23: 719.
27. Sekine Y, Bowen LK, Heidler KM, et al. Role of passenger leukocytes in allograft rejection: effect of depletion of donor alveolar macrophages on the local production of TNF-alpha, T helper 1/T helper 2 cytokines, IgG subclasses, and pathology in a rat model of lung transplantation. J Immunol 1997; 159: 4084.
28. Hibbs MS, Hasty KA, Seyer JM, et al. Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem 1985; 260: 2493.
29. Belperio JA, DiGiovine B, Keane MP, et al. Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation 2002; 73: 591.
30. Sumitomo M, Sakiyama S, Tanida N, et al. Difference in cytokine production in acute and chronic rejection of rat lung allografts. Transpl Int 1996; 9 Suppl 1: S223.
31. Mal H, Dehoux M, Sleiman C, et al. Early release of proinflammatory cytokines after lung transplantation. Chest 1998; 113: 645.
32. Rizzo M, SivaSai KS, Smith MA, et al. Increased expression of inflammatory cytokines and adhesion molecules by alveolar macrophages of human lung allograft recipients with acute rejection: decline with resolution of rejection. J Heart Lung Transplant 2000; 19: 858.
33. Iacono A, Dauber J, Keenan R, et al. Interleukin 6 and interferon-gamma gene expression in lung transplant recipients with refractory acute cellular rejection: implications for monitoring and inhibition by treatment with aerosolized cyclosporine. Transplantation 1997; 64: 263.
34. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106: 145.
35. Trello CA, Williams DA, Keller CA, et al. Increased gelatinolytic activity in bronchoalveolar lavage fluid in stable lung transplant recipients. Am J Respir Crit Care Med 1997; 156: 1978.
36. Inaki N, Tsunezuka Y, Kawakami K, et al. Increased matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase activity and expression in heterotopically transplanted murine tracheas. J Heart Lung Transplant 2004; 23: 218.
37. Campbell LG, Ramachandran S, Liu W, et al. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 2005; 5: 517.
38. Apparailly F, Noel D, Millet V, et al. Paradoxical effects of tissue inhibitor of metalloproteinases 1 gene transfer in collagen-induced arthritis. Arthritis Rheum 2001; 44: 1444.
39. Corcoran ML, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 1995; 270: 13453.
40. Chesler L, Golde DW, Bersch N, Johnson MD. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995; 86: 4506.
41. Bertaux B, Hornebeck W, Eisen AZ, Dubertret L. Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. J Invest Dermatol 1991; 97: 679.
42. Sandler C, Ekokoski E, Lindstedt KA, et al. Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C. Inflamm Res 2005; 54: 304.
43. Salek-Ardakani S, So T, Halteman BS, et al. Protein kinase Ctheta controls Th1 cells in experimental autoimmune encephalomyelitis. J Immunol 2005; 175: 7635.
44. Maquart FX, Pasco S, Ramont L, et al. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Crit Rev Oncol Hematol 2004; 49: 199.
45. Capello D, Rossi D, Gaidano G. Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol Oncol 2005; 23: 61.
46. Loren AW, Tsai DE. Post-transplant lymphoproliferative disorder. Clin Chest Med 2005; 26: 631.
47. Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155.
48. Beckers A, Bazin H. Incidence of spontaneous ileocecal immunocytomas in hybrids of LOU/C rats and rat strains with low spontaneous tumor incidence. J Natl Cancer Inst 1978; 60: 1505.
49. Guedez L, Stetler-Stevenson WG, Wolff L, et al. In vitro suppression of programmed-cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998; 102: 2002.
50. Oelmann E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 2002; 99: 258.
51. Corry DB, Rishi K, Kanellis J, et al. Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol 2002; 3: 347.